Lifecore Biomedical (LFCR) grants 30,000 RSUs to legal chief

Rhea-AI Filing Summary

Lifecore Biomedical’s Chief Legal & Administration officer, Thomas D. Salus, was granted an equity award reported as 30,000 shares of common stock at a price of $0.00 per share. This represents a grant, award, or other acquisition rather than an open-market purchase.

Footnotes explain that the award consists of restricted stock units that convert into common stock of Lifecore Biomedical, Inc. on a 1-for-1 basis. These restricted stock units will vest on the third anniversary of the grant date. Following this award, Salus directly holds 270,978 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Salus Thomas D.

(Last) (First) (Middle)

C/O LIFECORE BIOMEDICAL, INC.

3515 LYMAN BLVD.

(Street)

CHASKA MN 55318

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LIFECORE BIOMEDICAL, INC. \DE\ [ LFCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal & Administration

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		30,000	A	(1)(2)	270,978	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

2. Restricted Stock Units will vest on the 3rd anniversary of the grant date.

Remarks:

	/s/ Aaron S. Perlitsh, Attorney-In-Fact for Thomas D Salus	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lifecore Biomedical (LFCR) report for Thomas D. Salus?

Lifecore Biomedical reported that Thomas D. Salus received an equity award of 30,000 shares of common stock at $0.00 per share, classified as a grant, award, or other acquisition under a Form 4 insider transaction.

What type of equity did Thomas D. Salus receive from Lifecore Biomedical (LFCR)?

Thomas D. Salus received restricted stock units that convert into common stock of Lifecore Biomedical, Inc. on a 1-for-1 basis. The Form 4 lists the security as common stock with a grant-type transaction code A.

When will the restricted stock units granted to Thomas D. Salus at Lifecore Biomedical (LFCR) vest?

The restricted stock units granted to Thomas D. Salus will vest on the third anniversary of the grant date. Vesting means the units become earned and can convert into common stock according to the plan’s terms and conditions.

How many Lifecore Biomedical (LFCR) shares does Thomas D. Salus own after this Form 4 transaction?

After this transaction, Thomas D. Salus is reported as directly owning 270,978 shares of Lifecore Biomedical common stock. This figure reflects his holdings following the grant, as disclosed in the Form 4 ownership table.

Was the Lifecore Biomedical (LFCR) Form 4 transaction a purchase or a grant?

The transaction was reported as a grant, award, or other acquisition rather than a market purchase. The Form 4 uses transaction code A and shows a price of $0.00 per share, indicating a compensation-related equity award.